DOCSLIB.ORG

I @ Folateantagonistsalsoillustrated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
I @ Folateantagonistsalsoillustrated [CANCER RESEARCH 39, 293-304, February 1979] 0008-5472/79/0039-0000$02.00 Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture1 Joseph R. Bertlno2 Yale University School of Medicine, New Haven, Connecticut 06510 dylate synthetase per se or as facilitators of 5-fluorodeox yuridine 5'-monophosphate binding to this enzyme are also discussed. The potential for selectivity using nonclassical @ I folateantagonistsisalsoillustrated;inadditiontoBaker's antifol (triazinate), a triazine folate antagonist, now in clinical trial, several 2,4-diaminoquinazolines were found to be potent exhibitors of DNA synthesis in human leukemic leukocytes. Drug resistance to antineoplastic agents continues to be an important clinical problem. By using resistanceto meth otrexate as an example, exploitation of drug-resistant mu tants by design of specific inhibitors is possible. A strategy h for the prevention of drug resistance is advanced, based on F dataderivedfromexperimentalsystems.Itisconcluded —@-@ that large doses of drugs used in intermittent fashion and @1 sequentially in combination may be the best strategy to avoid this problem. An example of this strategy is Adriamy cin-cyclophosphamide-Oncovin-methotrexate-1 -f3-D-arabi nofuranosylcytosine, a five-drug sequential combination used to treat diffuse histiocytic lymphoma. Dr. Miller, Mr. and Mrs. Rosenthal, members and guests of the American Association for Cancer Research, I am deeply honored to receive the Rosenthal Award. I have been extremely fortunate over the years I have been at Yale to have many outstanding colleagues, fellows, I and graduate students, and they havereally been responsi ble for whatever success we have had. I had prepared a list of their names to show you but decided not to; it might embarrass those who wish not to admit an association, and it was embarrassing to me to realize I have accomplished so little with so much talent. I will acknowledge their respective contributions during the course of this lecture. Abstract The history of chemotherapy has not been characterized by smooth sailing. There have been many Bermuda trian Approaches to improving the selectivity of drugs for the gles along the way, and the success achieved has surprised treatment of patients with cancer are discussed, with em many scientists who doubted that progress was possible phasis on folate antagonists as prototype compounds. The with the deficiencies in our basic knowledge of the neoplas useof metabolites (leucovorin, 5-methyltetrahydrofolate)as tic process. What will the role of chemotherapy be in the “rescue' ‘ agents following methotrexate treatment with next decade? I was going to indicate in Table 1 that the appropriate monitoring of blood levels of methotrexate has 1980's would establish chemotherapy as an alternative to led to the safe use of this antimetabolite in high doses and surgery or radiation therapy for the treatment of some an improved therapeutic index for the use of this drug in human cancers, but since some of my best friends are some human cancers. The use of methotrexate in conjunc surgeons and radiation therapists, I decided not to strain tion with fluorouracil administration is sequence dependent our relationships. in experimental tumor models and is being tested in human I had the good fortune to have Frank Huennekens and tumors. New folate antagonists, designed to inhibit thymi Clem Finch as my mentors while a postdoctoral fellow quite a few years ago, and then to work with Arnold Welch and I Presented at the 1978 Meeting of the American Association for Cancer the “gangoffour―(Dr.Evangelo Canellakis, Dr. Robert Research in Washington, D. C. Supported in part by Grants CAO8O1Oand Handschumacher, Dr. William Prusoff, and Dr. Alan C. CA08341 and Contract NO-1-CM-33711. 2 American Cancer Society Professor of Medicine and Pharmacology. Sartorelli) at Yale for several more years; therefore it's Received October 16, 1978; accepted October 26, 1978. probably not surprising that my approach to chemotherapy FEBRUARY 1979 293 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1979 American Association for Cancer Research. J. R. Bertino Table 1 MIX@ Historyof chemotherapy:the pessimist'sview 1940's Chemotherapycan't work—wedon't understandthe dif @,MTX(G)N ferencebetweennormal and cancercells. @MTX@ @ ‘ Purines(C2,C1) 1950's Chemotherapyis effective, but patientsalwaysrelapse. DHFRMTx(G)N 1960's Chemotherapy can cure choriocarcinoma and Burkitt's FH2(G).@- u.FH4(G)N― lymphoma,but theseare unusualtumors. 1970's Chemotherapycancure severaltumors, but the drugs are @ dTMP FH4(G @N too toxic, i.e., lack selectivity. ‘I 1980's ? DNA dUMP Eztrocslhilor TT@ Compartment Cell Membrane Chart 1. Mechanism of MTx action and folate metabolism. 5CH3FH4, has been to try to understand why drugs work or don't MeFH4;5-CHOFH4, leucovorin. work. The following quote from GeorgeHitchings, who has done this as well as anyone fairly well summarizes this especially in the presence of NADPH and at a slightly acidic approach (64). pH (15). Under these conditions, the binding is one to one and has been referred to by the late Dr. William Werkheiser , ‘Historically most chernotherapeutic agents have been used without an understandingof their mechanismsof action. However, as “stoichiometric―(111,112). the potential rewardsof such understandingareenormous,for the Since thymidylate synthetase action, rather than FH4 practical application of the drug, the discovery of more selective formation via DHFR activity, is rate limiting, only when agents,and for fundamentalknowledge.― DHFR is completely inhibited and when excess or “free― MTX is present in the cell, as emphasized by Goldman, With that preamble, I would like to review for you some of Sirotnak, and coworkers, does FH4 synthesis stop and, our studies and indicate the approaches we are taking in consequently, thymidylate biosynthesis (32, 52, 100). Cells our current research. rapidly synthesizing DNA will of course be depleted of FR, During the past 20 years, a relatively complete description most rapidly. Since FR, is also required for purine synthe of how one clinically useful drug, MTX,3 exerts its effects sis, purine deficiency may also occur; as shown by Hryniuk on cells has become available. I would like to review this et a!. (66), this may be an important mechanism of cell information briefly for those who are not working in this death in some cell types. field (Chart 1). Therefore, some of the factors that relate to cell death In order to prevent a cell from replicating, MTX must first due to MTX are the level of excess or free MTX in cells, the cross the cell membrane. Work from several laboratories rate of dissociation of MTX from the inhibited enzyme when has shown that MTX uptake is an active process and that intracellular levels decrease as a function of decreasing this drug enters cells predominantly by utilizing the carrier extracellular levels, the rate of synthesis of DNA, and the system responsible for transport of reduced folates (10, 11, rate of synthesis of the target enzyme DHFR (9, 19, 21, 65, 17, 39, 50, 51, 53, 56, 67, 85, 99). Since MTX competes 104). effectively with the naturally occurring folates for uptake, it In recent years, as a result of studies in several laborato follows that high extracellular concentrations of this drug ries, it has become clear that the folate coenzymes in cells will inhibit uptake of MeFH4, the predominant form of folate exist as polyglutamates and that these compounds, rather in plasma. Thus an additional site of action of MTX, espe than being inactive storage forms, are the natural cofactors cially as used in the high-dose regimens, may be to starve for one-carbon enzyme reactions (33, 34). Recent studies cells of reduced folates. When extracellular concentrations have indicated some conversion of MTX to a diglutamate of MeFH4 or 5-formyltetrahydrofolate (leucovorin) are in form in vivo (8, 113) and in vitro (83). The consequences of creased by administration of these compounds, effective this conversion are not clear; however, this derivative is as inhibition of MTX transport may result. In addition, as potent an inhibitor of DHFR as is MTX (70). A mutant line of leucovorin enters the cell, because of countertransport, Chinese hamster ovary cells has recently been shown to be more MTX leaves the cell (85). Thus leucovorin may amelio unable to synthesize folate polyglutamates (80, 106). These rate MTX toxicity not only by providing cells with a reduced cells cannot survive without the addition of the end prod folate coenzyme, thus bypassing the MTX block, but also ucts of folate metabolism, namely, a purine and thymidine, by decreasing the intracellular concentration of MTX as a indicating that the formation of folate polyglutamates is result of these effects on its transport (51, 85). Obviously, essential for cell growth, perhaps because these forms are the higher the concentration of leucovorin relative to MTX, retained by the cell, while folate monoglutamates are not. the more important are these effects. Clearly, we need to learn a great deal more about folate Once inside the cell, MTX rapidly binds to the enzyme polyglutamate forms and cell regulation. DHFR. This binding, although reversible, is extremely tight, How can we use what information we have on folate metabolism to improve the selectivity of folate antagonist chemotherapy? Since stem cells from normal renewal tis 3 The abbreviations used are: MTX, methotrexate; MeFH4, 5-methyltetra hydrofolate; DHFR, dihydrofolate reductase; FH4, tetrahydrofolate; ALL, sues also utilize the same pathways to synthesize DNA as acute lymphatic leukemia; 5-FU, 5-fluorouracil; CNS, central nervous system; do tumor cells, how can we get selective antitumor effects? i.t., intrathecal; dThd, thymidine; CPG,, carboxypeptidase G, TZT, triazin The realization that MTX, like other antimetabolites, is a ate; FdUMP, fluorodeoxyuridine 5'-monophosphate; CH,FH4, 5,10- methylenetetrahydrofolate; FdUrd, fluorodeoxyuridine; cDNA, complemen schedule-dependent drug, i.e.
Load more

Recommended publications
  • Overview of Antiviral Medications Used in Ophthalmology
    ANTIVIRALS Overview of antiviral medications Jeremy Hoffman Clinical Research used in ophthalmology Fellow: International Centre for Eye Health, As eye health professionals, London School of Hygiene & Tropical we are fortunate to have Medicine, UK. a number of antiviral medications available in our armoury to treat a range of ophthalmic viral infections. This article provides an overview of what antiviral agents are available for these conditions, detailing their regimen SANDIP DAS SANYAM (SAGARMATHA CHOUDHARY EYE HOSPITAL, NEPAL) SANDIP DAS SANYAM(SAGARMATHA and evidence that Aciclovir – either as topical eye ointment or systemic tablets – is still the first-line antiviral in the treatment of many viral eye diseases around the supports their use. world, including here in Nepal. phthalmic viral infections, particularly herpes associated with toxicity, including superficial punctate simplex keratitis, have been at the forefront of keratopathy, chemical conjunctivitis, punctal occlusion Othe development of antiviral medications. and occasional serious hypersensitivity reactions. Idoxuridine was also unable to penetrate the corneal The discovery of the first targeted antiviral agent, epithelium to treat stromal or endothelial keratitis. in common with penicillin (the first antibiotic), owes much to serendipity. In 1959, William Prusoff With the advent of aciclovir in 1982, most herpetic developed idoxuridine (IDU) as a potential systemic ophthalmic infections became treatable, including anti-cancer agent. Idoxuridine those caused by herpes
    [Show full text]
  • Meeting Report: 26Th International Conference on Antiviral Research Q
    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
    [Show full text]
  • Applications of Traditional Chinese Medicine in Antiviral and Anticancer Drug Development
    YALE JOURNAL OF BIOLOGY AND MEDICINE 93 (2020), pp.381-384. Interview Applications of Traditional Chinese Medicine in Antiviral and Anticancer Drug Development An Interview with Dr. Yung-Chi (Tommy) Cheng, PhD Huaqi Li* MPH Candidate, Yale School of Public Health, Yale University, New Haven, CT You studied chemistry in Taiwan and then went During that period, there was a course offered at into a PhD in biochemical pharmacology at Brown University that invited several pharmacology Brown University. Can you tell us about how professors from other campuses to teach. Among those you first became interested in these fields? was Professor Prusoff who was an expert in antiviral and I was always interested in chemistry and the biologi- cancer research. He synthesized the first antiviral drug cal aspects of chemistry, so my undergraduate major was for the herpes simplex virus (HSV) and I was interested actually a double major in chemistry and biology. So, in that subject, so I decided to do my postdoc with him when I was deciding what to do after my undergraduate at Yale. I came over after receiving my PhD degree and training, I decided to go abroad and applied to universities that was the first time I was exposed to virology. Through in Canada. I was at the University of Guelph for one year. bioassays, we identified a nucleoside analog that was My wife was studying at Brown University, so I reapplied highly selective against HSV-1 and then the question was to Brown, but they didn’t really have a biochemistry de- how could this compound have such selectivity? Because partment, so I needed to decide what specific specialty of before that time, nobody believed that you could come biochemistry I was interested in.
    [Show full text]
  • Remarks by Jon Soderstrom*
    REMARKS BY JON SODERSTROM* Senator Birch Bayh has made the most significant impact on the U.S. and global economy of any individual who has ever come before and who lives today, full stop. That’s an amazing accomplishment. We have heard about all the legislative feats that he accomplished. We’ve heard about what an amazing legislator, attorney, and public servant he was. But, there are very few human beings who have had the impact on our economy that Senator Bayh had. It’s an amazing accomplishment and something that we should be in awe of. I’m going to give you a few statistics. I’m not going to overwhelm you; I’m going to bring it down to a personal level. I promised Kitty that I wouldn’t cry. Because when I was thinking about this the other day, it’s hard. If you knew Senator Bayh, he wore his emotions on his sleeve, and we have cried together. Here are just a couple statistics that should blow you away. The Bayh- Dole Act1 unleashed the technologies that were being developed in universities in a way that no one probably could have imagined. It was immediate and it was dramatic. The year was 1980. Prior to 1980—and I know because my entire career arc has followed the senator’s accomplishments—I was at graduate school studying the economy and what patents were doing, et cetera. At that time, the federal government, by law, was the owner of all intellectual property created with federal dollars and, as a result, it had created 28,000 patents.2 Less than 5 percent of those patents had ever been licensed or commercialized, compared with 25 percent to 30 percent of the small number of federal patents for which the government had allowed companies to retain title to the invention.3 That is “because the government would only grant nonexclusive licenses to patents it owned,” so * Managing Director, Office of Cooperative Research at Yale University.
    [Show full text]
  • ISAR News Vol
    August 2013 ISAR News Vol. 23 No. 1 Report on the 26th ICAR 11–15 May 2013, San Francisco, CA, USA President’s message (Phillip Furman) and Scientific Meeting Report. They have been inte- gral in maintaining a productive working relationship The 26th ICAR is now behind us and I am pleased to with Elsevier, publisher of Antiviral Research and report that the conference was a great success. The So- International Medical Press, publisher of Antiviral ciety has invested a significant amount of work over Therapy. The Society wishes to thank International the past years in revitalizing the annual meeting. Medical Press for publishing ISAR News for several These efforts have been recognized and affirmed by years and for publishing issue 22.2 in the last issue the results of our post-conference surveys, which pro- of AVCC (February 2013) which has now ceased pub- vided considerable positive feedback along with con- lication. Because of this, the Society had no publisher structive suggestions and comments. Thanks to all of for ISAR News. Thanks to the efforts of Mike Bray, you who have responded to these important surveys. Hugh Field, and Anthony Vere Hodge, Elsevier will The success of this year’s ICAR is due to a talented now publish ISAR News and the Scientific Meeting team of dedicated individuals with whom I had the Report in Antiviral Research. The smooth transition privilege of working to plan the conference. First, was greatly assisted by Alina Helsloot (Elsevier) who thanks go to the ISAR officers Joe Colacino, Past Pre- came to ICAR.
    [Show full text]
  • Rational Design and Synthesis of New Nucleoside Analogues Bearing a Cyclohexane Core
    Rational Design and Synthesis of New Nucleoside Analogues Bearing a Cyclohexane Core Beatriz Domínguez Pérez Ph.D. Thesis Ph.D. in Chemistry Supervisors: Dr. Ramon Alibés Arqués Dr. Félix Busqué Sánchez Dr. Jean-Didier Márechal Departament de Química Facultat de Ciències 2015 Memòria presentada per aspirar al Grau de Doctor per Beatriz Domínguez Pérez Beatriz Domínguez Pérez Vist i plau, Dr. Ramon Alibés Arqués Dr. Félix Busqué Sánchez Dr. Jean-Didier Maréchal Bellaterra, 13 de maig de 2015 “When you make the finding yourself-even if you’re the last person on Earth to see the light- you’ll never forget it” Carl Sagan A mis padres, a mi hermana A Jonatan Table of contents Abbreviations................................................................................................................................ 1 I. General introduction ............................................................................................. 5 1. Viruses ................................................................................................................................. 7 1.1. Virus replication ............................................................................................................. 8 1.2. Viral diseases in humans ................................................................................................ 9 2. Antiviral drugs ................................................................................................................... 10 2.1. Nucleoside analogues .................................................................................................
    [Show full text]
  • I @ Folateantagonistsalsoillustrated;Inadditiontobaker's
    [CANCER RESEARCH 39, 293-304, February 1979] 0008-5472/79/0039-0000$02.00 Toward Improved Selectivity in Cancer Chemotherapy: The Richard and Hinda Rosenthal Foundation Award Lecture1 Joseph R. Bertlno2 Yale University School of Medicine, New Haven, Connecticut 06510 dylate synthetase per se or as facilitators of 5-fluorodeox yuridine 5'-monophosphate binding to this enzyme are also discussed. The potential for selectivity using nonclassical @ I folateantagonistsisalsoillustrated;inadditiontoBaker's antifol (triazinate), a triazine folate antagonist, now in clinical trial, several 2,4-diaminoquinazolines were found to be potent exhibitors of DNA synthesis in human leukemic leukocytes. Drug resistance to antineoplastic agents continues to be an important clinical problem. By using resistanceto meth otrexate as an example, exploitation of drug-resistant mu tants by design of specific inhibitors is possible. A strategy h for the prevention of drug resistance is advanced, based on F dataderivedfromexperimentalsystems.Itisconcluded —@-@ that large doses of drugs used in intermittent fashion and @1 sequentially in combination may be the best strategy to avoid this problem. An example of this strategy is Adriamy cin-cyclophosphamide-Oncovin-methotrexate-1 -f3-D-arabi nofuranosylcytosine, a five-drug sequential combination used to treat diffuse histiocytic lymphoma. Dr. Miller, Mr. and Mrs. Rosenthal, members and guests of the American Association for Cancer Research, I am deeply honored to receive the Rosenthal Award. I have been extremely fortunate over the years I have been at Yale to have many outstanding colleagues, fellows, I and graduate students, and they havereally been responsi ble for whatever success we have had. I had prepared a list of their names to show you but decided not to; it might embarrass those who wish not to admit an association, and it was embarrassing to me to realize I have accomplished so little with so much talent.
    [Show full text]
  • Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19
    Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Antiviral Research 169 (2019) 104550 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Meeting report: 32nd International Conference on Antiviral Research T Enzo Tramontanoa, Bart Tarbetb, Jessica R. Spenglerc, Katherine Seley-Radtked, Chris Meiere, Robert Jordanf, Zlatko Janebag, Brian Gowenb, Brian Gentryh, José A. Estéi, Mike Brayj, Graciela Andreik, Luis M. Schangl,*, on behalf of the International Society for Antiviral Research a Department of Life and Environmental Sciences, University of Cagliari, Monserrato, Italy b Department of Animal, Dairy and Veterinary Sciences, Institute for Antiviral Research Utah State University, Logan, UT, USA c Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA d Department of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, USA e Department of Chemistry, Organic Chemistry, Faculty of Sciences, Universität Hamburg, Martin-Luther-King-Platz 6, 20146, Hamburg, Germany f Vir Biotechnology, Inc, San Francisco, CA, USA g Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nam.
    [Show full text]
  • Therapy of Cutaneous Herpes Simplex Virus Type 1 Infection in Guinea Pigs Susan Wong Yale University
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1978 5-iodo-5'-amino-2',5'-dideoxyuridine (AIU) therapy of cutaneous herpes simplex virus type 1 infection in guinea pigs Susan Wong Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Wong, Susan, "5-iodo-5'-amino-2',5'-dideoxyuridine (AIU) therapy of cutaneous herpes simplex virus type 1 infection in guinea pigs" (1978). Yale Medicine Thesis Digital Library. 3322. http://elischolar.library.yale.edu/ymtdl/3322 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. YALE medical library Digitized by the Internet Archive in 2017 with funding from The National Endowment for the Humanities and the Arcadia Fund https://archive.org/details/5iodo5amino25did00wong 5-IODO-5*-AMINO-2*,5'-DIDEOXYURIDINE (AIU) THERAPY OF CUTANEOUS HERPES SIMPLEX VIRUS TYPE 1 INFECTION IN GUINEA PIGS Susan Wong B.A. University of California, Los Angeles 1971 M.A* Yale University 1973 A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine Yale University School of Medicine New Haven, Connecticut 1978 Me4 Lib T\ >3 YiZ ZVZV ACKNOWLEDGEMENT I vould like to express my appreciation and gratitude to all those who contributed to this project.
    [Show full text]
  • Conference Report
    Antiviral Research 111 (2014) 143–153 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Meeting Report Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA ⇑ R. Anthony Vere Hodge ,1 Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 27th International Conference on Antiviral Research (ICAR) was held in Raleigh, North Carolina, USA Received 15 August 2014 from May 12 to 16, 2014. This article summarizes the principal invited lectures. John Drach (Elion Award) Accepted 18 August 2014 described the early days of antiviral drugs and their novel modes of action. Piet Herdewijn (Holy´ Award) Available online 16 September 2014 used evolutionary pressure to select DNA polymerases that accept nucleoside analogs. Replacing thymine by 5-chlorouracil led to the generation of a new form of Escherichia coli. Adrian Ray (Prusoff Award) dem- Keywords: onstrated how prodrugs can markedly improve both the efficacy and safety of potential drugs. The key- Human immunodeficiency virus note addresses, by David Margolis and Myron Cohen, tackled two emerging areas of HIV research, to find Hepatitis B virus an HIV ‘‘cure’’ and to prevent HIV transmission, respectively. These topics were discussed further in other Hepatitis C virus Ebola virus presentations – a cure seems to be a distant prospect but there are exciting developments for reducing Antiviral therapy HIV transmission. TDF-containing vaginal rings and GSK-744, as a long-lasting injection, offer great hope. There were three mini-symposia. Although therapy with TDF/FTC gives excellent control of HBV replica- tion, there are only a few patients who achieve a functional cure.
    [Show full text]
  • Medicine@Yale
    Medicine@Yale Advancing Biomedical Science, Education and Health Care Volume 2, Issue 4 July/August 2006 A faster pipeline speeds new treatments from lab to patient fi ce of Cooperative Research (ocr), catalyzing the creation of brand-new to obtain Food and Drug Administra- Small biotechs which takes the lead in licensing the companies tailored to the needs of tion (fda) approval to test one of with big ambitions fruits of faculty labors to biotechnol- particular therapies. Crews’s cancer drugs in people. ogy and pharmaceutical companies, The result has been a signifi cant Likewise, Achillion Pharmaceu- hasten drug testing currently lists a dozen additional contraction of the time it takes to ticals, a start-up company whose potential therapies under license and move new treatments from licensing fi rst compound was discovered by The fl ow of discoveries from the medi- poised to start early stage clinical trials to fi rst trials in humans. For example, Yung-Chi “Tommy” Cheng, ph.d., cal school’s labs to patients in need (see graphic, p. 6). Proteolix, founded in 2003 to com- the Henry Bronson Professor of is proceeding at a blistering pace—in This unprecedented success in mercialize compounds discovered by Pharmacology, began a Phase I trial the last four years, no fewer than fi ve pushing investigators’ fi nds out of Craig M. Crews, ph.d., associate pro- of the drug to treat hiv⁄aids only new therapies invented by School of the lab comes from ocr’s strategy fessor of molecular, cellular and devel- a year and half after the company’s Medicine researchers have advanced of partnering with up-and-coming opmental biology and pharmacology, inception.
    [Show full text]
  • Yale Medicine Magazine
    yale medicine autumn 2003 ’Round and ’round Local take on For sensory expert, the a global outbreak a taste of success early days of dna 24 30 14 16 autumn 2003 yale medicine CONTENTS 2 Letters 4 Chronicle 8 Rounds 10 Findings 12 Books 13 On Campus 14 Capsule on the cover 16 Building a better drug Academic researchers in pharma- The rational approach to drug discovery is changing cology have long relied on intuition to advance the process of drug pharmacology, but serendipity and imagination still play discovery. Even in today’s more a starring role. technology-driven and “rational” By Marc Wortman environment, there’s nothing like an inspired hunch. 24 Illustration by Gary Clement When a global outbreak becomes local For the shoe-leather work of public health, Connecticut officials seek help from Yale’s disease detectives. By Jennifer Kaylin 30 A matter of taste Debunking myths and shattering stereotypes has long been part of Linda Bartoshuk’s career path. By Peter Farley 34 Faculty 38 Students 46 Alumni 56 Faces 62 In Memoriam 64 Follow-Up 64 Archives On the Web info.med.yale.edu/ymm On our website, readers can submit class notes or a change of address, check the alumni events calendar, arrange for a lifelong Yale e-mail alias through the virtual Yale Station and search our electronic archive. 2 letters from the editor 3 the rest of the profession. The of going to my office and talk- People may think that you are ery. My experience is described The things that matter yale medicine conclusion is obvious: state ing with my patients, then I irrelevant, but as long as you are in a chapter in a book called Alumni Bulletin of the boards should recognize that it will move to another phase of convinced that you are not, you Doctors Afield, published by Yale As one can see from these pages, our mailbag has been Yale University School of Medicine Autumn 2003, Volume 38, No.
    [Show full text]